Michael A Kozminski1, Peter J Neumann2, Eric S Nadler3, Aleksandra Jankovic1, Peter A Ubel1,4. 1. Center for Behavioral and Decision Sciences in Medicine, University of Michigan Medical School, Ann Arbor, MI (MAK, AJ, PAU) 2. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA (PJN) 3. Charles Sammons Cancer Center, Baylor University Medical Center, Dallas, TX (ESN) 4. Ann Arbor Veterans Affairs Medical Center, the Division of General Internal Medicine, Ann Arbor, MI (PAU)
Abstract
OBJECTIVE: To determine how oncologists value quality-enhancing v. life-prolonging outcomes attributable to chemotherapy. METHODS: The authors surveyed a random sample of 1379 US medical oncologists (members of the American Society of Clinical Oncology), presenting them with 2 scenarios involving a hypothetical new chemotherapy drug. Given their responses, the authors derived the implicit cost-effectiveness ratios each physician attributed to quality-enhancing and life-prolonging chemotherapies. RESULTS: The authors received responses from 58% of the oncologists surveyed. On average, the responses implied that oncologists were willing to prescribe treatments that cost $245,972 per quality-adjusted life-year (QALY; SD $243,663 per QALY) in life-prolonging situations v. only $119,082 per QALY (SD $197,048 per QALY) for treatments that improve quality of life but do not prolong survival (P < 0.001). This difference did not depend on age, gender, percentage of time in clinical work, or self-reported preparedness to use and interpret cost-effectiveness information (P > 0.05 for all specifications). Differences across these situations persisted even among those who considered themselves to be "well-prepared" to make cost-effectiveness decisions. CONCLUSION: Cost-effectiveness thresholds for oncologists vary widely for life-prolonging chemotherapy compared to treatments that only enhance quality of life. This difference suggests that oncologists value length of survival more highly than quality of life when making chemotherapy decisions.
OBJECTIVE: To determine how oncologists value quality-enhancing v. life-prolonging outcomes attributable to chemotherapy. METHODS: The authors surveyed a random sample of 1379 US medical oncologists (members of the American Society of Clinical Oncology), presenting them with 2 scenarios involving a hypothetical new chemotherapy drug. Given their responses, the authors derived the implicit cost-effectiveness ratios each physician attributed to quality-enhancing and life-prolonging chemotherapies. RESULTS: The authors received responses from 58% of the oncologists surveyed. On average, the responses implied that oncologists were willing to prescribe treatments that cost $245,972 per quality-adjusted life-year (QALY; SD $243,663 per QALY) in life-prolonging situations v. only $119,082 per QALY (SD $197,048 per QALY) for treatments that improve quality of life but do not prolong survival (P < 0.001). This difference did not depend on age, gender, percentage of time in clinical work, or self-reported preparedness to use and interpret cost-effectiveness information (P > 0.05 for all specifications). Differences across these situations persisted even among those who considered themselves to be "well-prepared" to make cost-effectiveness decisions. CONCLUSION: Cost-effectiveness thresholds for oncologists vary widely for life-prolonging chemotherapy compared to treatments that only enhance quality of life. This difference suggests that oncologists value length of survival more highly than quality of life when making chemotherapy decisions.
Authors: V Valentí; J Ramos; C Pérez; L Capdevila; I Ruiz; L Tikhomirova; M Sánchez; I Juez; M Llobera; E Sopena; J Rubió; R Salazar Journal: Clin Transl Oncol Date: 2019-09-26 Impact factor: 3.405
Authors: Carolyn Miller Reilly; Deborah Watkins Bruner; Sandra A Mitchell; Lori M Minasian; Ethan Basch; Amylou C Dueck; David Cella; Bryce B Reeve Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603
Authors: Peter A Ubel; Scott R Berry; Eric Nadler; Chaim M Bell; Michael A Kozminski; Jennifer A Palmer; William K Evans; Elizabeth L Strevel; Peter J Neumann Journal: Health Aff (Millwood) Date: 2012-04 Impact factor: 6.301
Authors: Karen A Autio; Antonia V Bennett; Xiaoyu Jia; Michael Fruscione; Tomasz M Beer; Daniel J George; Michael A Carducci; Christopher J Logothetis; Robert C Kane; Laura Sit; Lauren Rogak; Michael J Morris; Howard I Scher; Ethan M Basch Journal: J Oncol Pract Date: 2013-06-25 Impact factor: 3.840
Authors: Philip Wahlster; Mireille Goetghebeur; Sandra Schaller; Christine Kriza; Peter Kolominsky-Rabas Journal: Health Res Policy Syst Date: 2015-04-28